pharmaphorum

JULY 18, 2022

It then elicits an immune response against that spike protein. You have a response with immunoglobulins type G (antibodies) and robust cellular response with both CD4 and CD8 T-cells being activated,” Morgon states. We get a higher immune response with the inhaled compared to the injectable,” Morgon relays.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

pharmaphorum

SEPTEMBER 2, 2020

Jounce will lead development of JTX-1811 through IND clearance, after which Gilead will have the sole right to develop the drug. Results presented for the drug at ASCO 2018 showed only one partial response out of seven gastric cancer patients given vopratelimab, and two partial responses when the drug was paired with Opdivo.

Licensing 71

Licensing Licensing Antibody Immune Response 71

BioTech 365

NOVEMBER 10, 2020

TScan Therapeutics Announces Partnership with QIAGEN to Develop T Cell-Based Laboratory Test for Comprehensive COVID-19 Immune Response TScan Therapeutics Announces Partnership with QIAGEN to Develop T Cell-Based Laboratory Test for Comprehensive COVID-19 Immune Response QIAGEN Secures Option to License Discoveries … Continue reading → (..)

Immune Response 40

Immune Response Development Licensing Licensing 40

pharmaphorum

APRIL 14, 2022

Epcoritamab is a bispecific antibody which targets CD3 on white blood cells and CD20 on tumour cells, and is designed to encourage an immune response against the cancer. The post AbbVie preps filings for lymphoma bispecific licensed from Genmab appeared first on. billion product at peak.

Licensing 64

Licensing Licensing Immune Response Antibody 64

Pharmaceutical Technology

JANUARY 19, 2023

It has been developed using the company’s recombinant nanoparticle technology. The findings showed that the Nuvaxovid booster dose increased immune responses compared to higher levels associated with the protection in Phase III clinical trials.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

XTalks

SEPTEMBER 5, 2023

Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

XTalks

APRIL 26, 2021

After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease. Malaria Vaccine Phase II Trial.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

pharmaphorum

APRIL 8, 2022

billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. Once within the tumour, it stimulates receptors on immune cells to mount an attack on the cancer. It was shown to activate cell-killing immune responses via natural killer (NK) and CD8+ cells, as well as antigen-presenting cells.

Drugs 105

Drugs Immune Response Licensing Licensing 105

Pharmaceutical Technology

AUGUST 12, 2022

The concept behind this form of treatment is that the introduction of these cells will enhance the immune response to disease, often through bioengineering the immune cells to have improved functionality and characteristics, such as longer half-lives. There are also 19 drugs in preclinical development (Table 1).

Development 130

Development Drugs Immune Response Marketing 130

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. is biotechnology company focused on developing radiopharmaceutical imaging and therapy agents.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 30, 2020

Genmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity in a proof-of-concept trial. Developing enapotamab vedotin formed a major part in the rationale behind the company’s $506 million Nasdaq IPO last year.

Development 52

Development Drugs Antibody Immune Response 52

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. The EU says its advance purchase order will finance part of the upfront costs of developing the vaccine.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

pharmaphorum

DECEMBER 6, 2022

Moderna claims that Comirnaty infringes its patents covering a chemical modification to prevent an unwanted immune response in patients and allow larger doses to be delivered, as well as a proprietary lipid nanoparticle formulation. The post Pfizer/BioNTech strike back in Moderna COVID vaccine lawsuit appeared first on.

Vaccination 97

Vaccination Vaccine Immune Response Sales 97

The Pharma Data

DECEMBER 17, 2020

San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response.

Immune Response 52

Immune Response Engineer Development Licensing 52

XTalks

JUNE 21, 2024

The company is developing unique therapeutic assets with strategic visions. With headquarters in Gaithersburg, MD, US and London, UK, Revolo Biotherapeutics is focused on developing therapies that reset the immune system to achieve superior efficacy and long-term disease remission without compromising the immune system.

Development 52

Development Immune Response Drugs Regulation 52

pharmaphorum

AUGUST 27, 2020

The Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), works with universities, research organisations, businesses, charities, and government to develop a supportive ecosystem. The first is that the development of vaccines is utilising cutting edge technologies.

Vaccination 122

Vaccination Vaccine Life Science Clinical Trials 122

pharmaphorum

OCTOBER 21, 2022

Swiss pharma giant Roche has moved to strengthen its position in the KRAS-mutated cancer space through a $25 million licensing and collaboration agreement with Austrian arenaviral technology firm Hookipa Pharma. Roche also has the option to license a second, undisclosed, novel arenaviral immunotherapy.

Licensing 52

Licensing Licensing Immune Response Engineer 52

XTalks

AUGUST 13, 2020

In a press statement , Kaiser Permanente outlined that in this phase of the trial, data will be collected about the safety, immune response and efficacy of the vaccine candidate as required for regulatory review.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

pharmaphorum

AUGUST 24, 2020

With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius and its pipeline of drugs for cancer and fibrotic diseases. BMS seems to be interested mainly in AVID200’s potential in cancer, however, at least initially.

Immune Response 59

Immune Response Antibody Drugs Development 59

pharmaphorum

SEPTEMBER 23, 2021

Development of the shot eventually fell behind mRNA rivals from BioNTech and Moderna, and Imperial eventually pivoted its efforts to development of possible boosters directed at emerging variants based on its self-assembling RNA (saRNA) platform. billion takeover of Translate Bio and $470 million acquisition of Tidal Therapeutics.

RNA 52

RNA Immune Response Vaccination Vaccine 52

The Pharma Data

FEBRUARY 22, 2021

(Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. vice president of immunology at Lilly.

Development 40

Development Clinical Development Clinical Trials Clinical Trials 40

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . Our ambition is to develop life-changing treatments for patients.

Immune Response 52

Immune Response Licensing Licensing Sales 52

The Pharma Data

APRIL 8, 2022

The mere motions of breathing are known to influence vital functions of the lungs, including their development in babies, the production of air-exchange-enhancing fluid on their inner surfaces, and maintenance of healthy tissue structure. a Wyss Technology Development Fellow at the Institute. During his Ph.D.

Immune Response 52

Immune Response In-Vivo Genetic Analysis Research 52

The Pharma Data

JANUARY 12, 2021

Biond Biologics announced today that it has entered into a potentially $1 billion global licensing agreement with Sanofi to take a joint stab at defeating advanced forms of cancer with a more comprehensive and expedited approach to immuno-oncology. . It is being developed for the treatment of solid tumors.

Immune Response 52

Immune Response Clinical Trials Clinical Trials Development 52

The Pharma Data

SEPTEMBER 30, 2021

Our results show that the candidate vaccine formulation is safe, produces rapid immune responses – within seven days – and elicits comprehensive immunity against SARS-CoV-2,” said Varadarajan. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccination 52

Vaccination Vaccine Immune Response Licensing 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The joint development team is working on improving the temperature stability of the mRNA vaccine candidate and targeting a -20°C storage temperature for late-stage clinical trials and at launch.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

JUNE 24, 2022

It also developed the first single-dose drug therapy that can be used to eradicate malaria caused by Plasmodium vivax – tafenoquine – and is working on an improved TB vaccine which has been licensed to the Bill & Melinda Gates Foundation. The new unit will operate on a non-profit basis, said GSK in a statement.

Vaccination 59

Vaccination Vaccine Immune Response Development 59

pharmaphorum

AUGUST 26, 2022

Among the claims is that Comirnaty was developed using a chemical modification to prevent causing an unwanted immune response in patients which was discovered by Moderna scientists, and that the use of a lipid nanoparticle formulation also infringes its intellectual property. Lawsuits sprouting like mushrooms.

Vaccination 59

Vaccination Vaccine Sales Immune Response 59

The Pharma Data

JUNE 26, 2021

We’ve all witnessed the promise of mRNA technology during this pandemic and are now looking to extend that promise to select annual vaccines ”, said Jean-François Toussaint, Global Head of Research and Development, Sanofi Pasteur. “ Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

NOVEMBER 2, 2022

CSL’s vaccines unit CSL Seqirus division is paying Arcturus $200 million upfront to gain access to its self-amplifying mRNA technology platform and exclusive licenses to several vaccine candidates, with another $4.3 billion on offer in milestones if the programmes meet development and commercial objectives.

Vaccination 52

Vaccination Vaccine Immune Response Gene Therapy 52

The Pharma Data

AUGUST 28, 2020

Oxford coronavirus vaccine triggers immune response. The UK remains under the jurisdiction of the European Medicines Agency and its licensing scheme until the end of the Brexit transition period on 31 December 2020. UK signs deals for 90 million virus vaccine doses. Source link.

Vaccination 52

Vaccination Vaccine Immune Response Medicine 52

pharmaphorum

DECEMBER 21, 2020

The agreement sees San Diego-based Janux in line for around $500 million in milestones apiece for two T-cell engager therapies – which bind to a tumour cell and recruit a patient’s T cells to eradicate tumour cells – that will be developed using Janux’ TRACTr platform.

Immune Response 59

Immune Response Sales Antibody Drugs 59

pharmaphorum

MAY 31, 2022

billion in potential development milestones, to get its hands on the ASP3772 shot, which recently claimed a breakthrough designation from the FDA for the treatment of pneumococcal disease in older adults. The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot.

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

pharmaphorum

FEBRUARY 8, 2022

The initial assessment of AT845 is based on four patients who received two doses of the gene therapy, with no evidence of serious adverse events, according to Astellas’ head of clinical development for gene therapies Weston Miller. Shares in the drugmaker rose just over 1% after the FORTIS data was announced.

Gene Therapy 52

Gene Therapy Gene Immune Response Licensing 52

pharmaphorum

JANUARY 7, 2021

The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients. Equally important to the company is the safety data gathered as the technology is used as the pharma companies use it to guide development of cancer immunotherapies.

Immune Response 53

Immune Response Doctor Doctors Pharma Companies 53

pharmaphorum

SEPTEMBER 8, 2022

A malaria vaccine developed by members of the University of Oxford team behind the AstraZeneca COVID-19 jab has been hailed as a possible game-changer in the fight against the deadly parasitic infection. g) dose of Novavax’ Matrix-M adjuvant, used to boost the immune response to the R21 antigen. g) or high (50 ?g)

Vaccination 72

Vaccination Vaccine Immune Response Antibody 72